Our Work.

Repurposing non-cancer generic drugs is a game-changing strategy to quickly develop affordable treatment options for cancer patients.

Accelerating Drug Development

It would take years to review the thousands of published research studies on generic drugs tested as cancer treatments to identify the most promising candidates.

Our technology, which uses AI and machine learning, reduces this time to a matter of weeks.

Closing the Funding Gap

A market failure for finding new uses for off-patent and inexpensive generic drugs means that there is no funding for the clinical trials needed to change the standard of care.

We are creating an innovative and sustainable model for clinical trial funding.

Reaching Doctors and Patients

Our fractured healthcare ecosystem makes it challenging to broadly change the standard of care for patients based on new evidence with generic drugs.

We are collaborating with stakeholders to influence adoption of new treatments in routine medical practice.

Fast Forward

Google.org

The Greater Sum Foundation

IBM Research Science for Social Good Initiative

Biden Cancer Institute & WeWork Collaboration Hubs

Massachusetts Biotechnology Council (MassBio)

Life Science Cares

Bain & Company Inspire

Omdena

Boston University

Tufts University

Innoplexus

GLG

Cancer Research UK & University College London

CCC19: COVID-19 and Cancer Consortium

Dana-Farber Cancer Institute

Harvard Data Sciences Initiative

MIT PKG Public Service Center

MIT Volunteer Consulting Group

MIT Sloan School’s Entrepreneurship Lab

Northeastern University & Roux Institute

Day One Project

University of Pennsylvania

Yale University

Brown University

Costello Medical

Massachusetts Life Sciences Center

Harvard Innovation Labs

MassChallenge

Dynamic Corporate Solutions, Inc.

WilmerHale

Foley Hoag

The Commonwealth Institute

Brandeis University

Bowdoin College

Colby College

Bates College

Unleashed PR